InMed Pharmaceuticals Inc. (INM): Price and Financial Metrics
GET POWR RATINGS... FREE!
INM Stock Price Chart Interactive Chart >
INM Price/Volume Stats
| Current price | $0.80 | 52-week high | $3.51 |
| Prev. close | $0.80 | 52-week low | $0.65 |
| Day low | $0.76 | Volume | 23,000 |
| Day high | $0.80 | Avg. volume | 161,068 |
| 50-day MA | $0.87 | Dividend yield | N/A |
| 200-day MA | $1.35 | Market Cap | 11.70M |
InMed Pharmaceuticals Inc. (INM) Company Bio
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.
Latest INM News From Around the Web
Below are the latest news stories about InMed Pharmaceuticals Inc that investors may wish to consider to help them evaluate INM as an investment opportunity.
InMed Pharmaceuticals Inc. (INM) CEO Eric Adams on Q2 2022 Results - Earnings Call TranscriptInMed Pharmaceuticals Inc. (INM) Q2 2022 Earnings Conference Call February 15, 2022 14:00 ET Corporate Participants Colin Clancy - Senior Director of Investor Relations Eric Adams - President and Chief Executive Officer Bruce Colwill - Chief Financial Officer Eric Hsu - Senior Vice President, Preclinical Research and Development Alexandra Mancini... |
InMed Pharmaceuticals (INM): Generating Commercial Sales of CBC and CBTLONDON, UK / ACCESSWIRE / February 16, 2022 / InMed Pharmaceuticals' (INM's) Q222 financial results reflect its evolution from a pure-play biotech firm to one with commercial sales to the health and wellness market, with revenues of $0. As of January, it also began selling cannabicitran (CBT) to the health and wellness market. |
InMed Pharmaceuticals Strengthens its Commercial Leadership Team with the Appointment of Vice President of Sales and Marketing for BayMedicaVANCOUVER, British Columbia, Feb. 15, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, is pleased to announce the appointment of Gerard (Jerry) P. Griffin III as Vice President of Sales and Marketing at BayMedica, a wholly owned subsidiary of InMed. Mr. Griffin will oversee the commercialization of BayMedica’s health and wellness business including the exi |
InMed Pharmaceuticals Inc. (INM) Reports Q2 Loss, Tops Revenue EstimatesInMed Pharmaceuticals Inc. (INM) delivered earnings and revenue surprises of -29.17% and 6%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock? |
InMed Pharmaceuticals Reports Second Quarter Fiscal 2022 Financial Results and Provides Business UpdateCompleted acquisition of BayMedica, a rare cannabinoid manufacturing and commercialization company in the health and wellness sectorStrengthened IP with patent filing for use of rare cannabinoids for the treatment of neurodegenerative diseasesCommercial rollout of an additional rare cannabinoid, CBT- first of several rare cannabinoid launches planned for the first half of 2022Advanced the pharmaceutical drug development programs in EB, glaucoma and neurodegenerative diseases VANCOUVER, British C |
INM Price Returns
| 1-mo | -1.37% |
| 3-mo | -20.79% |
| 6-mo | -59.80% |
| 1-year | -72.88% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -38.93% |
| 2021 | -60.18% |
| 2020 | -44.61% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...